title: [Is statin use associated with D'Amico risk groups and biochemical recurrence after radical prostatectomy?].
abstract: OBJECTIVE
  To examine the association between statin use and prostate cancer (PC) stratified with D'Amico risk groups and biochemical recurrence (BR) in patients undergoing radical prostatectomy (RP).
  
  
  METHODS
  All medical charts of patients managed from 2004 to 2008 for PC with RP were reviewed retrospectively. The use and the type of statin were identified. Patients were split according to the use (S+) or not (S-) of statin. The two groups were compared using the Chi(2) test. A logistic regression was performed for multivariate analysis.
  
  
  RESULTS
  Overall, 377 patients were included. Mean age was 64 (48-76) (median, range). Ninety-seven patients (27.5%) used statin for at least a year. Groups S- and S+ were comparable in terms of age, obesity, diabetes, preoperative PSA, biopsy Gleason score or clinical stage. The use of statin was statistically associated with D'Amico risk groups (P=0.003). The number of high-risk PC was higher in Group S+ (23.7% vs. 10.7%) with an odds ratio of 2.4 (P=0.009). With a mean follow up of 33±10 months, the overall 2-years-BR was 89%. The 2-years-BR was higher in the S+ (93% vs. 88%, P=0.16). After adjustment, this difference was statistically significant with a hazard ratio of 0.46 (P=0.036).
  
  
  CONCLUSIONS
  The use of statin was associated with high risk PC in this study. Surprisingly, the statin use seem also to be associated with better disease-free survival, independently of other risk factors.
authors.affiliation: Clinique Pasteur, 45, avenue de Lombez, 31300 Toulouse, France. v.misrai@clinique-pasteur.com
authors.forename: V
authors.initials: V
authors.lastname: Misrai
authors.forename: C
authors.initials: C
authors.lastname: Do
authors.forename: J-M
authors.initials: JM
authors.lastname: Lhez
authors.forename: B
authors.initials: B
authors.lastname: Elman
authors.forename: I
authors.initials: I
authors.lastname: Latorzeff
authors.forename: D
authors.initials: D
authors.lastname: Portalez
authors.forename: P
authors.initials: P
authors.lastname: Grosclaude
mesh_terms: D000368:Aged; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality* / Q000473:pathology* / Q000601:surgery; D012189:Retrospective Studies; D018570:Risk Assessment
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017430:Prostate-Specific Antigen